jueves, 2 de junio de 2022

FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns | FDA

FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns | FDA

No hay comentarios:

Publicar un comentario